PPARγ Agonist from <i>Chromolaena odorata</i>

Zhang, Manli; Irwin, Dianne; Li, Xiaoning; Sauriol, Françoise; Shi, Xiaowei; Huo, Changhong; Li, Ligeng; Gu, Yu‐Cheng; Shi, Qing

doi:10.1021/np300386d

Cited by 41 publications

(19 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study provided compelling evidence that UA activated PPARγ; this finding was consistent with the previous observation that UA isolated from Chromolaena odorata acts as PPARγ agonist. 33 In addition, BADGE, a PPARγ antagonist, abolished the agonistic effect of UA on PPARγ. Co-treatment with UA and BADGE resulted in PPARγ levels similar to the control levels, and the changes in MMP2, MMP9, and TIMP1 expression were significantly diminished by BADGE co-treatment.…”

Section: Discussionmentioning

confidence: 98%

Ursolic acid reduces the metalloprotease/anti-metalloprotease imbalance in cerebral ischemia and reperfusion injury

Wang

Deng

2016

DDDT

View full text Add to dashboard Cite

BackgroundActivators of PPARs, particularly PPARγ, may be effective neuroprotective drugs against inflammatory responses in cerebral ischemia and reperfusion injury. Ursolic acid (UA) may act as a PPARγ agonist and serve as an anti-inflammatory agent. In this study, we used a rat middle cerebral artery occlusion and reperfusion model to examine how UA acts as a neuroprotective agent to modulate the metalloprotease/anti-metalloprotease balance.MethodsThe middle cerebral artery occlusion and reperfusion model (occlusion for 2 hours followed by reperfusion for 48 hours) was induced in male Sprague Dawley rats. UA was administered intragastrically 0.5, 24, and 47 hours after reperfusion. Bisphenol A diglycidyl ether (a PPARγ antagonist) was intraperitoneally administered 1, 24.5, and 47.5 hours after reperfusion. Forty-eight hours after reperfusion, neurological deficits and infarct volume were estimated. The PPARγ level and the metalloprotease/anti-metalloprotease balance were examined by Western blotting and immunohistochemistry. The activation of MAPK signaling pathways was also assessed.ResultsUA-treated (5, 10, or 20 mg/kg) rats showed significant improvement in neurological deficit score, infarct volume, and the number of intact neurons compared with control rats (P<0.01). Both the PPARγ protein level and the percentage of PPARγ-positive cells were increased in the UA-treated groups (P<0.01). Compared with the control group, the UA-treated groups exhibited reduced protein levels of MMP2, MMP9, and activated MAPKs (P<0.01) but an increased level of TIMP1 (P<0.01). UA exerted its protective effects in a dose-dependent manner. Co-treatment with UA and bisphenol A diglycidyl ether completely abolished the UA-induced changes in PPARγ expression; however UA continued to exert a significant but partial neuroprotective effect.ConclusionUA can act as a PPARγ agonist to improve the metalloprotease/anti-metalloprotease balance, possibly by inhibiting the activation of the MAPK signaling pathway, thereby attenuating cerebral ischemia and reperfusion injury. Therefore, UA may serve as a novel neuroprotective therapeutic agent.

show abstract

Section: Discussionmentioning

confidence: 98%

Ursolic acid reduces the metalloprotease/anti-metalloprotease imbalance in cerebral ischemia and reperfusion injury

Wang

Deng

2016

DDDT

View full text Add to dashboard Cite

show abstract

“…The proton at The NOESY experiment revealed a correlation between H-8 and 7′ which indicates the Z geometry of the double bond [17]. The HMBC spectrum showed the methoxy proton at δ 3.78 correlated Table 1 1 H NMR (400 MHz) and 13 C NMR (100 MHz) spectral data of compounds 1-3 (δ in ppm). with C-9 (δ 171.7), which confirmed the ester moiety.…”

Section: Structural Determinationmentioning

confidence: 93%

“…Chemical structures of all compounds. [11,12], (+)-medioresinol (5) [13], (+)-syringaresinol (6) [13], (+)-6-(4-hydroxy-3-methoxyphenyl)-3,7-dioxabicyclo [3.3.0]octan-2-one (7) [11], coumarin (8), 8-hydroxycoumarin (9), 5-hydroxycoumarin (10), 7-hydroxycoumarin (11), 4-hydroxybenzaldehyde (12), and vanillin (13).…”

Section: Structural Determinationmentioning

confidence: 99%

New lignan esters from Alyxia schlechteri and antifungal activity against Pythium insidiosum

et al. 2013

View full text Add to dashboard Cite

“…The leaves of C. odorata also contain the highest concentration of allelochemicals isolated from a plant (98). A study in Vietnam revealed that the aqueous extract of the leaf contained flavonoids (salvigenin, sakuranetin, isosakuranetin, kaempferide, betulenol, 2-5-7-3 tetra-o-methyl quercetagetin, tamarixetin, two chalcones and odoratin and its alcoholic compound), essential oils (geyren, bornyl acetate and β-eubeden), saponin triterpenoids, tannins, organic acids and numerous trace substances (99). Another study by Heiss et al (100)…”

Section: Chemical Constituents Of Chromolaena Odoratamentioning

confidence: 99%

Chromolaena odorata: A neglected weed with a wide spectrum of pharmacological activities

Vijayaraghavan

Rajkumar²,

Bukhari

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

The study of wound‑healing plants has acquired an interdisciplinary nature with a systematic investigational approach. Several biochemicals are involved in the healing process of the body, including antioxidants and cytokines. Although several pharmaceutical preparations and formulations are available for wound care and management, it remains necessary to search for efficacious treatments, as certain current formulations cause adverse effects or lack efficacy. Phytochemicals or biomarkers from numerous plants suggest they have positive effects on different stages of the wound healing process via various mechanisms. Several herbal medicines have displayed marked activity in the management of wounds and various natural compounds have verified in vivo wound healing potential, and can, therefore, be considered as potential drugs of natural origin. Chromolaena odorata (L.) R.M. King and H. Robinson is considered a tropical weed. However, it exhibits anti‑inflammatory, antipyretic, analgesic, antimicrobial, cytotoxic and numerous other relevant medicinal properties on an appreciable scale, and is known in some parts of the world as a traditional medicine used to treat various ailments. To understand its specific role as nature's gift for healing wounds and its contribution to affordable healthcare, this plant must be scientifically assessed based on the available literature. This review aims to summarize the role of C. odorata and its biomarkers in the wound healing activities of biological systems, which are crucial to its potential future drug design, development and application for the treatment of wounds.

show abstract

PPARγ Agonist from Chromolaena odorata

Cited by 41 publications

References 22 publications

Ursolic acid reduces the metalloprotease/anti-metalloprotease imbalance in cerebral ischemia and reperfusion injury

Ursolic acid reduces the metalloprotease/anti-metalloprotease imbalance in cerebral ischemia and reperfusion injury

New lignan esters from Alyxia schlechteri and antifungal activity against Pythium insidiosum

Chromolaena odorata: A neglected weed with a wide spectrum of pharmacological activities

Contact Info

Product

Resources

About